Hemostasis Today

October, 2026
October 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Mostafa Faisal: Donor Type and Long-Term Quality of Life After HCT for Severe Aplastic Anemia
Aug 23, 2026, 16:06

Mostafa Faisal: Donor Type and Long-Term Quality of Life After HCT for Severe Aplastic Anemia

Mostafa Faisal, Associate Professor of Clinical Hematology and HSCT at Assiut University, shared a post on X about a recent article by Matty Slaught et al., published in Transplantation and Cellular Therapy, adding:

“Comparison of Late Effects and Quality of Life by Donor Type in Long-Term Survivors of Severe Aplastic Anemia after Hematopoietic Cell Transplantation.

Long-term SAA HCT survivors:

  • 122 survivors; median 26 years after HCT
  • 49% employed full-time, 24% part-time
  • Common late effects: sexual dysfunction 35%, cataracts 20%, low bone density 20%
  • 34% required antihypertensive therapy

Alternative-donor HCT associated with more musculoskeletal problems (OR 9.9)

SF-36 physical 49.5 and mental 49.9, essentially identical to population norms

No major QOL differences by donor type

Lifelong surveillance remains essential, but long-term QOL is reassuring.”

Title: Comparison of Late Effects and Quality of Life by Donor Type in Long-Term Survivors of Severe Aplastic Anemia after Hematopoietic Cell Transplantation

Authors: Matty Slaught, Lynn Onstad, Paul A. Carpenter, Sioban B. Keel, Catherine J. Lee, Shivaprasad Manjappa, Lauri Burroughs, Rohtesh S. Mehta, Masumi Ueda Oshima, Phuong Vo, K. Scott Baker, Stephanie J. Lee, Neel S. Bhatt

Mostafa Faisal

Other posts featuring Mostafa Faisal on Hemostasis Today.